Last reviewed · How we verify
Taurolidine heparin
Taurolidine heparin is a combination antimicrobial and anticoagulant agent that prevents bacterial biofilm formation and thrombosis in vascular access devices.
Taurolidine heparin is a combination antimicrobial and anticoagulant agent that prevents bacterial biofilm formation and thrombosis in vascular access devices. Used for Prevention of catheter-related bloodstream infections in central venous catheters, Maintenance of hemodialysis catheter patency, Prevention of thrombosis in vascular access devices.
At a glance
| Generic name | Taurolidine heparin |
|---|---|
| Also known as | Tautolock HEP 500, Taurolock HEP 500 |
| Sponsor | Ain Shams University |
| Drug class | Antimicrobial/anticoagulant combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Vascular Access Management |
| Phase | FDA-approved |
Mechanism of action
Taurolidine is a broad-spectrum antimicrobial that disrupts bacterial cell membranes and prevents biofilm formation on catheter surfaces, while heparin provides anticoagulant activity to prevent thrombotic occlusion. This combination is used as a catheter lock solution to reduce catheter-related bloodstream infections and maintain patency in central venous catheters and hemodialysis access devices.
Approved indications
- Prevention of catheter-related bloodstream infections in central venous catheters
- Maintenance of hemodialysis catheter patency
- Prevention of thrombosis in vascular access devices
Common side effects
- Local catheter site reactions
- Bleeding or hematoma at insertion site
- Allergic reactions
Key clinical trials
- Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients (NA)
- Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) (PHASE3)
- Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age (PHASE4)
- Antimicrobial Locks for Hemodialysis Catheter Infections (PHASE2)
- Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection (PHASE3)
- Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
- Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (NA)
- Taurolidine in Haemodialysis Catheter Related Bacteraemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taurolidine heparin CI brief — competitive landscape report
- Taurolidine heparin updates RSS · CI watch RSS
- Ain Shams University portfolio CI